Video
27 Jul 2023

DAEWOONG PR VIDEO (EN)

Watch Video

We continue to take the initiative by making bold challenges and investments in R&D to leap forward as a global healthcare group. Following the 2022 launch of Fexuclue, a drug treating gastroesophageal reflux disease, the company released Envlo, a Type 2 diabetes treatment. By bolstering its R&D pipeline, Daewoong Pharmaceutical is developing first-in-class and best-in-class drugs.

Content provided by our supplier

Daewoong Pharmaceutical Co.,Ltd

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2015
  • Employees:
    1000 - 4999
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

Other Content from Daewoong Pharmaceutical Co.,Ltd (2)